Background--Accumulating evidence suggests that the balance between pathogenic effector T cells (Teffs) and regulatory T cells (Tregs) may be important for controlling atherosclerotic disease. We hypothesized that a combination therapy with anti-CD3 antibody (CD3-Ab) and IL-2/anti-IL-2 monoclonal antibody complex (IL-2 complex) aimed at increasing the ratio of Tregs to Teffs would effectively inhibit atherosclerosis in mice.
I
t is now widely accepted that inflammatory condition within the vessel wall is one of the most important factors for atherosclerosis development 1, 2 and contributes toward plaque instability, thrombotic arterial occlusion, and severe clinical events including acute coronary syndrome and stroke. Following accumulation into the subendothelial space or intima through the activated endothelium and differentiation into macrophages, monocytes take up modified low-density lipoprotein (LDL) particles, and differentiate into foam cells, which secrete pro-inflammatory cytokines causing activation of immune cells such as T cells. After antigen presentation or activation by macrophages or dendritic cells (DCs), na€ ıve CD4 + T cells differentiate into effector T cells (Teffs) such as T helper type 1 (Th1), T helper type 2 (Th2), and T helper type 17 (Th17) lineages, which all play an important role in atherogenesis in both humans and mice. 2 Th1 cells are known to promote atherosclerotic disease by producing inflammatory cytokines such as interferon-c. 3 However, the roles of Th2 or Th17-mediated immune responses in atherosclerosis remain controversial. Recently, immunoregulatory CD4 + T-cell subsets, namely regulatory T cells (Tregs) expressing CD25 (IL-2 receptor a-chain) molecule, have been shown to play a protective role in atherogenesis by dampening Teff responses. [4] [5] [6] [7] [8] The transcription factor Foxp3 (forkhead box P3) is a master regulator and the most reliable molecular marker for natural Tregs. 9 Recent study demonstrated that genetic depletion of Foxp3 + Tregs increased atherosclerotic lesions in atherosclerosis-prone mice by aggravating hypercholesterolemia. 10 In consideration of these previous studies,
we believe that increasing the Treg/Teff ratio, by suppressing Teff responses and promoting Treg responses, could be a promising therapeutic approach for atherosclerotic disease. Intravenous administration of anti-CD3-specific antibody (CD3-Ab) was shown to suppress Teff immune responses and to be effective for suppressing atherosclerotic process in mice, 11 autoimmune diabetes in mice and humans, and acute transplant rejection in humans. 12, 13 Previous studies demonstrated induction of CD4 + CD25 + Tregs, along with reduced number of Teffs, following CD3-Ab treatment, explaining the long-term protective effects observed in mouse models of autoimmune diseases, 12 although an increase in CD4 + CD25 + Treg number was absent in atherosclerosis-prone mice.
11
Despite these beneficial effects, high doses of CD3-Ab cannot be used because of severe side effects such as low levels of cytokine release from activated T-cells. 13 Thus, in addition to this antibody treatment, other therapeutic strategies to attain long-term therapeutic efficacy are needed. Recent studies have demonstrated that injection of a recombinant mouse IL-2/anti-IL-2 monoclonal antibody complex (IL-2 complex) could be one promising avenue for the expansion of CD4 + CD25 + Foxp3 + Tregs 14 and studies have
shown that this IL-2 complex therapy suppressed the development and progression of atherosclerosis 15, 16 and experimental autoimmune encephalitis 14 In the present study, we determined if the combination therapy of CD3-Ab and IL-2 complex would effectively inhibit atherosclerosis in ApoE À/À mice by enhancing regulatory immune responses. We propose the novel concept involving modulation of both effector and regulatory arms of T-cell immune responses could be an attractive therapeutic approach against atherosclerosis.
Methods

Animals and Experimental Design
Six-week-old ApoE À/À mice were fed a high-cholesterol diet containing 0.2% cholesterol and 21% fat (CLEA) and water ad libitum. For blockade of CD3, 50 lg of anti-CD3 antibody F (ab')2 (145-2C11; Bio X cell) or 50 lg of isotype-matched hamster immunoglobulin G F(ab')2 (control IgG) (Bio X cell) was intravenously injected into the mice for 5 consecutive days at 8 weeks of age. For IL-2 complex therapy, a recombinant mouse IL-2/anti-IL-2 mAb (JES6-1) complex (1 lg IL-2 plus 5 lg anti-IL-2 mAb) was given i.p. to the 9-week-old mice for 3 consecutive days, after which they received once weekly from 10 to 16 weeks of age. Mice were anaesthetized with an isoflurane and an intraperitoneal injection of pentobarbital (30 mg/kg body weight). Mice were housed in a specific pathogen-free animal facility at Kobe University, and all animal experiments were conducted in accordance to the Guidelines for Animal Experiments at Kobe University School of Medicine.
Atherosclerotic Lesion Assessments
Mice were anesthetized and the aorta was perfused with saline. The samples were cut in the ascending aorta, and the proximal samples containing the aortic sinus were embedded in OCT compounds (Tissue-Tek; Sakura Finetek 
Preparation of Peritoneal Macrophages
Ten-week-old ApoE À/À mice of each group were treated with 3% thiogycollate broth i.p. injection and sacrificed with isoflurane for peritoneal macrophage isolation after a 3-day treatment as described previously. 18 Cells were plated onto culture dishes with RPMI medium containing 10% FBS and incubated for 3 to 4 hours at 37°C and 5% CO 2 . The adhesive cells were used as macrophages for FACS analysis and RT-PCR analysis.
Real-Time RT-PCR Analysis
Total RNA was extracted from aortas or peritoneal macrophages after perfusion with RNA later (Ambion) using the TRIzol reagent (Invitrogen). For RT, a PrimeScript RT reagent Kit (Takara) was used. Quantitative PCR was performed using a SYBER Premix Ex Taq (Takara) and an ABI PRISM 7500 Sequence Detection System (Applied Biosystems) according to comparative threshold cycle method following manufacturer's protocol. The following primers were used to amplify CD4, CD25, Foxp3, CTLA-4, iNOS, MCP-1, CXCL10, Arg I, in duplicate, and the fluorescence curves were analyzed with the software included with the ABI PRISM 7500 system. GAPDH was used as an endogenous control reference.
Statistical Analysis
Data were expressed as the meanAESEM. The Mann-Whitney U test was used to detect significant differences between 2 groups. The Kruskal-Wallis test was used to detect significant differences when comparing more than 3 groups, followed by post hoc Dunn's multi-comparison test. A value of P<0.05 was considered statistically significant. For statistical analysis, GraphPad Prism version 6.0 (GraphPad Software) was used.
Results
Effects of CD3 Ab, IL-2 Complex, or Combination Therapy on CD4 + T Cell Immune Responses
To compare the efficacy of CD3-Ab, IL-2 complex, and the combination therapy with CD3-Ab and IL-2 complex, 4 experimental groups were made as follows: IgG plus PBStreated (control-treated), CD3-Ab plus PBS-treated (CD3-Abtreated), IgG plus IL-2 complex-treated (IL-2 complex-treated), CD3-Ab plus IL-2 complex-treated (combination-treated) groups. As described in Figure 1A , ApoE These results indicate that the atheroprotective effect of CD3-Ab treatment could be mainly due to the depletion of Teffs in our experiments, although short-term treatment with CD3-Ab has been shown to increase the proportion of Foxp3 + Tregs at later time points. 13 As treatment with IL-2 complex has been reported to systemically increase Tregs but not Teffs, 14, 15 we next investigated the impact of IL-2 complex on immune responses including Tregs and Teffs according to the protocol described in Figure 1A . ( Figures 1B, 1D, and 1E 1E) . Notably, the Treg/Teff ratio was much higher in the spleen and LNs of the mice with the combination therapy compared with control-treated or CD3-Ab-treated mice ( Figure 1F ). T regulatory type 1 (Tr1) cell is another Treg subset that does not express Foxp3 and can clearly be detected by surface markers CD49b and lymphocyte activation gene 3 (LAG-3). 19 We observed that the combination therapy markedly increased the number of splenic Tr1 cells ( Figure 1G + Tregs from CD3-Ab/IL-2 complex-treated mice expressed higher levels of CD25, CD103, glucocorticoid-induced TNF receptor family-related gene/protein (GITR), cytotoxic T lymphocyte-associated protein 4 (CTLA-4) compared to those from control-treated or CD3-Ab-treated mice (Figure 2A ), implying an activated phenotype of Tregs after the combination therapy. In addition, a trend towards increased expression of Tregassociated molecules was seen in mice with IL-2 complex alone. We also investigated the effect of each therapy on surface maturation markers CD80 and CD86 in splenic CD11c + DCs. Neither CD3-Ab nor IL-2 complex monotherapy altered the expression of these maturation markers in splenic DCs, whereas we observed a modest but significant decrease in the expression of CD80, but not CD86, in splenic DCs of CD3-Ab/IL-2 complex-treated mice (Figure 2B ). To determine whether the combination treatment changed T-cell responses and polarization, we examined cytokine secretion from Th1/Th2 ratio was much lower in the spleen of the mice with the combination therapy compared with mice in other groups ( Figure 2D ). To determine the effects of CD3-Ab, IL-2 complex, or combination therapy on atherosclerosis development, we assessed the atherosclerotic lesion formation of the 4 experimental groups. No adverse effects were observed in all groups throughout the experiments. The mice receiving combined therapy showed a decrease in plasma total cholesterol and LDL cholesterol levels and an increase in triglyceride levels compared with control-treated mice, whereas no statistical differences in plasma lipid profiles were detected among the other 3 groups (Table) Figures 3A and 3B) .
Notably, CD3-Ab/IL-2 complex-treated mice showed a further reduction in atherosclerotic lesion formation (37.2AE1.9 910 4 lm 2 , Figures 3A and 3B ) compared with control-treated and each monotherapy mice. Consistent with this, the lipid content of the plaques in the aortic sinus was also significantly decreased in the CD3-Ab/IL-2 complex-treated mice compared to control-treated and each monotherapy mice ( Figure 3C ). In parallel with the cross-sectional studies, we performed en face analysis of thoracic aortas, revealing a significant reduction in aortic plaque burden in CD3-Ab/IL-2 complex-treated mice (3.74AE0.12%) compared with control mice (5.53AE0.23%) ( Figure 3D ). To determine the effects of each therapy on plaque composition, immunohistochemical studies of atherosclerotic lesions in the aortic sinus were performed. Collagen contents in atherosclerotic lesions were significantly increased in CD3-Ab-treated and CD3-Ab/IL-2 complex-treated mice compared to control-treated mice ( Figures 3A and 3E) . Although CD3-Ab or IL-2 complex monotherapy did not affect the recruitment of macrophages in atherosclerotic plaques, the lesions of CD3-Ab/IL-2 complex-treated mice showed a significant reduction in the macrophage accumulation compared to control mice ( Figures 3A and 3F ).
The Combination Therapy With CD3 Ab and IL-2 Complex Dramatically Enhances Regulatory Immune Responses in the Lesions
It has been reported that Tregs and Teffs migrate into atherosclerotic plaques and the lesional Treg/Teff balance may be important in controlling atherosclerotic process via diminishing inflammation within atherosclerotic plaques. 20 Immunohistochemical analysis revealed that IL-2 complex monotherapy did not affect the number of CD4 + T cells in atherosclerotic plaques, whereas CD3-Ab monotherapy or combination therapy showed a trend toward reduction in CD4 + T cell infiltration compared with control mice ( 
The Combination Therapy Induces Macrophage Polarization Toward a Less Inflammatory M2 Phenotype
To further reveal the mechanisms for reduced macrophage accumulation in the plaques, we examined the effects of the combination therapy on the monocyte number or macrophage phenotype change. We found that the number of CD11b + Ly6-C high monocytes were significantly decreased in the spleen of CD3-Ab/IL-2 complex-treated mice compared with controltreated mice ( Figure 5A ) and those monocytes expressed lower levels of CD115 (CSF-1 receptor), a growth factor receptor for CSF-1 involved in promoting atherosclerosis. 21 To examine whether the combination therapy affected the phenotype of macrophages in vivo, we induced inflammatory macrophage infiltration in the peritoneal cavity by thioglycollate injection as described previously. 18 We collected thioglycollate-induced peritoneal macrophages and performed flow cytometry and quantitative RT-PCR analysis.
Flow cytometry analysis of peritoneal macrophages revealed that the combination therapy significantly reduced CD11c + M1 macrophages and increased CD206 + M2 macrophages compared with control mice ( Figure 5B ). In contrast, there were no significant differences in the percentage of CD11c + M1 and CD206 + M2 macrophages among the other 3 groups.
Consistent with these results, quantitative RT-PCR analyses of peritoneal macrophages revealed that the combination therapy significantly decreased the expressions of M1 macrophage markers including iNOS, MCP-1, and CXCL-10, and increased the expressions of M2 macrophage markers including Arg I, Fizz1, and Ym-1 ( Figure 5C ). Furthermore, we examined the mRNA expressions of iNOS and Arg I in atherosclerotic aortas by quantitative RT-PCR and found decreased expression of iNOS and increased expression of Arg I in CD3-Ab/IL-2 complex-treated mice compared with control-treated mice ( Figure 5D ). These results suggest that athero-protective effects of the combination therapy may be partly due to the reduced number of inflammatory monocytes or polarization of macrophages toward a less inflammatory phenotype, as a result of dramatic up-regulation of regulatory immune responses.
Discussion
In the present study, we examined the impact of Teff depletion, Treg expansion, and both intervention on the Teff and Treg immune responses in both lymphoid organs and atherosclerotic plaque and on the development of atherosclerosis, using CD3-Ab, IL-2 complex, or the combination of CD3-Ab and IL-2 complex, respectively. Monotherapy with CD3-Ab or IL-2 complex alone induced a modest but significant reduction in atherosclerotic plaque formation compared with untreated mice, whereas therapeutic intervention of both Teffs and Tregs using CD3-Ab/IL-2 complex combination therapy further prevented atherosclerosis development compared with each monotherapy group. The beneficial effects of the combination therapy were associated with a dramatic increase in the Treg/Teff ratio, up-regulation of Treg activation markers in lymphoid organs and atherosclerotic plaques, the shift of Th1/Th2 balance to Th2 in lymphoid organs, a reduced number of proinflammatory Ly6C high monocytes in the spleen, and a conversion of the M1 to M2 macrophage state. This is the first report demonstrating that efficacy of IL-2 complex therapy in prevention of atherosclerosis can be greatly enhanced when combined with CD3-Ab. We believe that our findings are highly relevant for shaping future clinical strategies for preventing atherosclerotic diseases.
It is now clear that Teff immune responses are involved in accelerating atherosclerosis development and progression. Although we observed a modest decrease in the CD80 expression in splenic DCs of CD3-Ab/IL-2 complex-treated mice, whether the lesional suppression mechanisms through this pathway are involved in the reduction of atherosclerosis remains unclear and further studies are needed. To the best of our knowledge, we believe that this combination therapy is the most effective approach for specifically promoting regulatory immune responses. A recent study has demonstrated that hypercholesterolemia decreases the Treg/Teff ratio in atherosclerotic lesions via inhibiting Treg accumulation within plaques. 20 This implies the possibility that increasing proportion of Tregs in atherosclerotic lesions could be a hopeful strategy to dampen plaque inflammation and prevent atherosclerosis, although further extensive experiments are required to identify the exact role of intraplaque Tregs in atherogenesis. In this study, we showed that the marked reduction of atherosclerosis from combination therapy was associated with a dramatic increase in the Treg/Teff ratio and up-regulation of Treg activation markers not only in lymphoid organs but also in atherosclerotic plaques, implying that the beneficial effects of the combination therapy may partly be due to the induction of Tregs with activated phenotype in atherosclerotic plaques. Monocytes infiltration from the peripheral blood to the subendothelial space or intima followed by macrophage differentiation is believed to be critical in initiation of atherosclerosis in humans and animals. The extent of macrophage recruitment into atherosclerotic plaques may depend on the cholesterol levels or monocyte number in the blood. 27 In the present study, we found that the combination therapy significantly reduced proinflammatory Ly6C high monocytes compared to untreated or monotherapy groups, suggesting a possible contribution to decreased macrophage accumulation in atherosclerotic plaques. We found that thioglycollate-induced peritoneal macrophages from CD3-Ab/IL-2 complex-treated mice showed lower mRNA expressions of M1 markers and higher expressions of M2 markers. Regarding macrophage markers, a similar trend was observed in the atherosclerotic aortas of CD3-Ab/IL-2 complex-treated mice. Th1 cells are reported to contribute to generation of M1 macrophages, whereas Th2 cells promote generation of M2 macrophages. 28 In addition, IL-10 derived from Tregs induces STAT3 (Signal Transducer and Activator of Transcription 3) activation and drives M2 polarization in mice with severe combined immunodeficiency. 29 Collectively, we suppose that in CD3-Ab/IL-2 complex-treated mice, phenotype change of thioglycollate-induced peritoneal macrophages toward M2 phenotype may be attributable to dramatic expansion of Tregs as well as a shift from Th1 to Th2 immune responses, which represents one possible explanation for the athero-protective effects of the combination therapy.
In conclusion, we have demonstrated that combined intervention using CD3-Ab and IL-2 complex induced a remarkable inhibition of atherosclerosis via dramatically increasing the Treg/Teff ratio in lymphoid organs and atherosclerotic plaques, which caused macrophage polarization toward a less inflammatory M2 phenotype. Our data imply that therapeutic intervention aimed at enhancing Treg-mediated immune responses and limiting Teff-mediated immune responses might represent a novel therapeutic approach for atherosclerotic diseases.
